NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

血小板減少性疾病:市場考察,流行病學,市場預測

Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534858
出版日期 按訂單生產 內容資訊 英文 100 Pages
商品交期: 2-10個工作天內
價格
血小板減少性疾病:市場考察,流行病學,市場預測 Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 100 Pages
簡介

本報告提供血小板減少性疾病治療藥市場相關調查分析,疾病的背景,流行病學,主要7個國家 (美國、德國、西班牙、義大利、法國、英國、日本)的市場趨勢相關的系統性資訊。

第1章 主要考察

第2章 血小板減少性疾病:市場概要

第3章 疾病的背景和概要:血小板減少性疾病

  • 簡介
  • 血小板減少性疾病的原因
  • 病因
  • 病理生理學
  • 病因學
  • 症狀
  • 診斷和治療等

第4章 流行病學和患者族群

  • 主要調查結果
  • 族群與預測參數
  • 主要7個國家的血小板減少性疾病患者族群
  • 各國血小板減少性疾病的流行病學
    • 美國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 日本

第5章 未滿足需求

第6章 上市藥

第7章 Octagam:Octapharma USA

第8章 Nplate (AMG-531):Amgen

第9章 MULPLETA (Lusutrombopag):鹽野義製藥

第10章 Privigen:CSL Behring

第11章 Rhophylac:CSL Behring

第12章 新興治療

第13章 申請、階段III藥

第14章 階段II藥

第15章 血小板減少性疾病:市場分析

第16章 血小板減少性疾病:主要7個國家的綜合市場規模

第17章 血小板減少性疾病的市場規模:各國

  • 美國:市場分析
  • 預測血小板減少性疾病:EU5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本:市場分析

第18章 推動市場要素

第19章 市場障礙

第20章 附錄

第21章 DelveInsight的功能

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI0225

DelveInsight's "Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Thrombocytopenia epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Thrombocytopenia Understanding and Treatment Algorithm

The market report provides the overview of the Thrombocytopenia by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Thrombocytopenia Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Thrombocytopenia in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Thrombocytopenia Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Thrombocytopenia Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Thrombocytopenia market.

Thrombocytopenia Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Thrombocytopenia Report Insights

  • Patient Population in Thrombocytopenia
  • Therapeutic Approaches in Thrombocytopenia
  • Thrombocytopenia Pipeline Analysis
  • Thrombocytopenia Market Size and Trends
  • Thrombocytopenia Market Opportunities
  • Impact of upcoming Therapies in Thrombocytopenia

Thrombocytopenia Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Thrombocytopenia Report Assessment

  • Current Treatment Practices in Thrombocytopenia
  • Unmet Needs in Thrombocytopenia
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Thrombocytopenia market
  • Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia market
  • To understand the future market competition in the Thrombocytopenia market.

Table of Contents

1. Report Introduction

2. Thrombocytopenia Market Overview at a Glance

  • 2.1. Market Share Distribution of Thrombocytopenia in 2016
  • 2.2. Market Share Distribution of Thrombocytopenia in 2028

3. Disease Background and Overview: Thrombocytopenia

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Thrombocytopenia in 7MM
  • 4.3. Total Prevalent Patient Population of Thrombocytopenia in 7MM - By Countries

5. Epidemiology of Thrombocytopenia by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.1.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.1.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.1.5. Diagnosed Cases of the Thrombocytopenia
    • 5.1.6. Treatable Cases of the Thrombocytopenia
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.4.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.4.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.4.5. Diagnosed Cases of the Thrombocytopenia
    • 5.4.6. Treatable Cases of the Thrombocytopenia
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.5.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.5.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.5.5. Diagnosed Cases of the Thrombocytopenia
    • 5.5.6. Treatable Cases of the Thrombocytopenia
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.6.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.6.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.6.5. Diagnosed Cases of the Thrombocytopenia
    • 5.6.6. Treatable Cases of the Thrombocytopenia
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.7.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.7.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.7.5. Diagnosed Cases of the Thrombocytopenia
    • 5.7.6. Treatable Cases of the Thrombocytopenia
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.8.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.8.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.8.5. Diagnosed Cases of the Thrombocytopenia
    • 5.8.6. Treatable Cases of the Thrombocytopenia
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Thrombocytopenia
    • 5.9.3. Sub-Type Specific cases of the Thrombocytopenia *
    • 5.9.4. Sex- Specific Cases of the Thrombocytopenia *
    • 5.9.5. Diagnosed Cases of the Thrombocytopenia
    • 5.9.6. Treatable Cases of the Thrombocytopenia

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Thrombocytopenia

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Thrombocytopenia

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Thrombocytopenia : 7MM Market Analysis

  • 12.1. 7MM Market Size of Thrombocytopenia
  • 12.2. 7MM Percentage Share of drugs marketed for Thrombocytopenia
  • 12.3. 7MM Market Sales of Thrombocytopenia by Products

13. Thrombocytopenia : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Thrombocytopenia in United States
    • 13.1.2. Percentage Share of drugs marketed for Thrombocytopenia in United States
    • 13.1.3. Market Sales of Thrombocytopenia by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Thrombocytopenia in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Thrombocytopenia in Germany
      • 13.2.1.3. Market Sales of Thrombocytopenia by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Thrombocytopenia in France
      • 13.2.2.2. Percentage Share of drugs marketed for Thrombocytopenia in France
      • 13.2.2.3. Market Sales of Thrombocytopenia by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Thrombocytopenia in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Thrombocytopenia in Italy
      • 13.2.3.3. Market Sales of Thrombocytopenia by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Thrombocytopenia in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Thrombocytopenia in Spain
      • 13.2.4.3. Market Sales of Thrombocytopenia by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Thrombocytopenia in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Thrombocytopenia in United Kingdom
      • 13.2.5.3. Market Sales of Thrombocytopenia by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Thrombocytopenia in Japan
    • 13.3.2. Percentage Share of drugs marketed for Thrombocytopenia in Japan
    • 13.3.3. Market Sales of Thrombocytopenia by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Thrombocytopenia in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Thrombocytopenia in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Thrombocytopenia in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Thrombocytopenia in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Thrombocytopenia in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Thrombocytopenia in United States (2016-2028)
  • Table 7: Treatable Cases of the Thrombocytopenia in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Thrombocytopenia in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Thrombocytopenia in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Thrombocytopenia in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Thrombocytopenia in Germany (2016-2028)
  • Table 12: Treatable Cases of the Thrombocytopenia in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Thrombocytopenia in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Thrombocytopenia in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Thrombocytopenia in France (2016-2028)
  • Table 16: Diagnosed Cases of the Thrombocytopenia in France (2016-2028)
  • Table 17: Treatable Cases of the Thrombocytopenia in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Thrombocytopenia in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Thrombocytopenia in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Thrombocytopenia in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Thrombocytopenia in Italy (2016-2028)
  • Table 22: Treatable Cases of the Thrombocytopenia in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Thrombocytopenia in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Thrombocytopenia in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Thrombocytopenia in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Thrombocytopenia in Spain (2016-2028)
  • Table 27: Treatable Cases of the Thrombocytopenia in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Thrombocytopenia in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Thrombocytopenia in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Thrombocytopenia in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Thrombocytopenia in UK (2016-2028)
  • Table 32: Treatable Cases of the Thrombocytopenia in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Thrombocytopenia in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Thrombocytopenia in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Thrombocytopenia in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Thrombocytopenia in Japan (2016-2028)
  • Table 37: Treatable Cases of the Thrombocytopenia in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 42:7MM- Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 45: United States-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 48: Germany-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 51: France-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 54: Italy-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 57: Spain-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 60:UK-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Table 63: Japan-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Thrombocytopenia in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Thrombocytopenia in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Thrombocytopenia in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Thrombocytopenia in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Thrombocytopenia in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Thrombocytopenia in United States (2016-2028)
  • Figure 7: Treatable Cases of the Thrombocytopenia in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Thrombocytopenia in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Thrombocytopenia in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Thrombocytopenia in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Thrombocytopenia in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Thrombocytopenia in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Thrombocytopenia in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Thrombocytopenia in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Thrombocytopenia in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Thrombocytopenia in France (2016-2028)
  • Figure 17: Treatable Cases of the Thrombocytopenia in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Thrombocytopenia in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Thrombocytopenia in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Thrombocytopenia in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Thrombocytopenia in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Thrombocytopenia in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Thrombocytopenia in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Thrombocytopenia in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Thrombocytopenia in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Thrombocytopenia in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Thrombocytopenia in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Thrombocytopenia in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Thrombocytopenia in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Thrombocytopenia in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Thrombocytopenia in UK (2016-2028)
  • Figure 32: Treatable Cases of the Thrombocytopenia in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Thrombocytopenia in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Thrombocytopenia in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Thrombocytopenia in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Thrombocytopenia in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Thrombocytopenia in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 45: United States-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 51: France-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 60:UK-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Thrombocytopenia in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Thrombocytopenia by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Thrombocytopenia by Therapies in USD MM (2016-2028)